« Return to News | Ethics/Regulatory

Kantara Initiative, SAFE-Biopharma support NSTIC principles

Wednesday, July 3, 2013 10:41 AM

The Kantara Initiative, which helps organizations establish verified trust in use of digital identities for business and government services, and SAFE-Biopharma, which provides a global digital identity and digital signature standard for the life sciences, have pledged to adopt the four principles of the National Strategy for Trusted Identities in Cyberspace (NSTIC), the White House initiative to improve the privacy, security and convenience of sensitive online transactions.

The four NSTIC principles are 1) privacy enhancing and voluntary, 2) secure and resilient, 3) interoperable and 4) cost-effective and easy-to-use.

NSTIC aims to protect individuals, businesses and public agencies from the costs of cyber-crimes while ensuring internet support of innovation and its role as a marketplace. NSTIC calls for development of an identity ecosystem—interoperable technology standards and policies—in which individuals, organizations and underlying infrastructure such as routers and servers can be authoritatively authenticated.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.